Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C
Resources
Showing 291 to 300 of 359 resources
-
Bridging the gap: Why some people are not offered the medicines that NICE recommends
The extent of variation in the uptake of NICE recommended medicines across the NHS in England has been described before. The reasons for such variations are less well understood. IMS Health conducted a qualitative study during the summer and autumn of 2012 to help investigate the reasons for that variation. Eight therapy areas were discussed during interviews with experts, including hepatitis C (HCV).England Nov 2012 Reports & Research PDF -
Hepatitis C Testing and Treatment in Wirral. Increasing Treatment Places: A Practical Solution
The following report describes the practical steps taken by the local partnership in Wirral in the wake of the Department of Health’s 2002 publication of the ‘Hepatitis C Strategy for England: Getting Ahead of the Curve’, aimed at systematically increasing hepatitis C awareness and testing in Wirral in such a way as to increase demand for treatment places. In doing so, the partnership hoped to tangibly reduce local hepatitis C prevalence and the associated burden of treatment in the longer term.North West Oct 2012 Reports & Research PDF -
Increasing hepatitis B and C testing in the prison setting: The use of new diagnostics at HMP Manchester
Hepatitis B and C pose a major challenge to public health in the UK. Up to half a million people have one or both of these viruses, which can cause liver failure and cancer, yet only a minority have been diagnosed. Prevalence is particularly high in the prison population; evenNorth West Sep 2012 Case study, Reports & Research, Strategy & Planning PDF -
Burden of Liver Disease and Inequalities in the North West of England
This report presents data on liver disease in the North West of England, describing the burden by age, sex, deprivation and geography. It explores routinely available data for the main causes of liver disease; alcohol, hepatitis B and C and fatty liver disease. It is a useful resource for Directors of Public Health, health and wellbeing boards, commissioners and providers of services and others involved in liver disease.North West Sep 2012 Reports & Research PDF -
Evaluation of the pilot provision of single use plastic water ampoules to people who inject drugs in Glasgow
Greater Glasgow and Clyde (GG&C) has an estimated injecting population of 8862. There are 74 Injecting Equipment Provision (IEP) outlets across the area to meet the paraphernalia needs of this population. Since 2009 GG&C has provided a comprehensive package of paraphernalia, including needle choice, spoons, filters, citric acid and swabs. However, until the start of this pilot, water for injecting (WFI) was not available from any of the 62 pharmacy outlets. In fact prior to the pilot only 3 outlets provided WFI and this was in a glass ampoule form.Scotland Sep 2012 Case study, Reports & Research PDF -
Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965
Hepatitis C virus (HCV) is an increasing cause of morbidity and mortality in the United States. Many of the 2.7–3.9 million persons living with HCV infection are unaware they are infected and do not receive care (e.g., education, counseling, and medical monitoring) and treatment. CDC estimates that although persons born during 1945–1965 comprise an estimated 27% of the population, they account for approximately three fourths of all HCV infections in the United States, 73% of HCV-associatedRest of World 17 Aug 2012 Reports & Research PDF -
Hepatitis C in the UK - 2012 Report
The most recent national estimates in 2012 suggested that around 216,000 individuals were chronically infected with hepatitis C (HCV) in the UK. Both hospital admissions and deaths from HCV-related end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) are continuing to rise. In England, statistical modelling predicts that 15,840 individuals will be living with HCV-related cirrhosis or HCC in England in 2020 if left untreated.UK Jul 2012 Reports & Research PDF -
National survey of hepatitis C services in prisons in England, July 2012
This is the first dedicated survey of hepatitis C services in prisons in England. The survey aim was to collect basic information on what type of services are provided in prisons for the diagnosis, treatment and follow-up of prisoners infected by hepatitis C.England Jul 2012 Reports & Research PDF -
NHS Liver Care E-seminar: Making Every Contact Count
This document provides a summary of the key points made by Professor Martin Lombard, National Clinical Director for Liver Disease, during an NHS presentation he gave. He provides an overview of the high prevalence of liver disease in England and discusses the reasons for this high prevalence and what measures could be taken to lower the number of cases of liver disease. The document also provides a link to listen to the e-seminar.England 13 Jun 2012 Other MS Word -
Hepatitis C Prevalence and Incidence among Scottish Prisoners and Staff Views of its Management: Final Report
This report aims to generate reliable data on prevalence and incidence of hepatitis C to inform the Scottish Prison Service and the NHS to develop effective needs-led interventions for hepatitis C (HCV) infected prisoners, and to enable an informed assessment of the effectiveness of measures to prevent the spread of blood borne viruses, especially hepatitis C, within the prison setting, as outlined in the Hepatitis C (Phase (II)) Action Plan for Scotland (2008).England, Scotland May 2012 Reports & Research PDF